MX2020013210A - Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica. - Google Patents

Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.

Info

Publication number
MX2020013210A
MX2020013210A MX2020013210A MX2020013210A MX2020013210A MX 2020013210 A MX2020013210 A MX 2020013210A MX 2020013210 A MX2020013210 A MX 2020013210A MX 2020013210 A MX2020013210 A MX 2020013210A MX 2020013210 A MX2020013210 A MX 2020013210A
Authority
MX
Mexico
Prior art keywords
kidney disease
chronic kidney
diabetes
methods
treating subjects
Prior art date
Application number
MX2020013210A
Other languages
English (en)
Inventor
Bill Symonds
Steve Piscitelli
Karen Segal
Ruby Holder
Sophie Bozec
Sebastien Bolze
Pascale Fouqueray
Christophe Arbet-Engels
Julie Dubourg
Paul Strumph
Brandon Dale Swift
Margaret Smith Fletcher
Original Assignee
Metavant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metavant Sciences Gmbh filed Critical Metavant Sciences Gmbh
Publication of MX2020013210A publication Critical patent/MX2020013210A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación está dirigida a un método para tratar la prediabetes o la diabetes mellitus tipo 1 o tipo 2 que comprende administrar a un sujeto que lo necesite una cantidad eficaz de imeglimina, en donde el sujeto padece una enfermedad renal crónica.
MX2020013210A 2018-06-06 2019-06-06 Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica. MX2020013210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681391P 2018-06-06 2018-06-06
PCT/US2019/035789 WO2019236844A1 (en) 2018-06-06 2019-06-06 Methods of treating subjects having diabetes with chronic kidney disease

Publications (1)

Publication Number Publication Date
MX2020013210A true MX2020013210A (es) 2021-02-26

Family

ID=67253960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013210A MX2020013210A (es) 2018-06-06 2019-06-06 Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.

Country Status (15)

Country Link
US (2) US11266652B2 (es)
EP (1) EP3801542B1 (es)
JP (1) JP2021529728A (es)
KR (1) KR20200130281A (es)
CN (1) CN111918655B (es)
AU (1) AU2019282727A1 (es)
BR (1) BR112020024643A2 (es)
CA (1) CA3102412A1 (es)
ES (1) ES2929994T3 (es)
IL (1) IL279174A (es)
MX (1) MX2020013210A (es)
PH (1) PH12020551159A1 (es)
SG (1) SG11202007172YA (es)
TW (1) TWI846700B (es)
WO (1) WO2019236844A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003243A (es) 2017-10-02 2020-09-18 Poxel Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
WO2019236844A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CN112218623A (zh) 2018-06-14 2021-01-12 博希尔公司 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂
EP4142795A4 (en) * 2020-04-27 2024-05-22 The Research Institute at Nationwide Children's Hospital PPAR AGONISTS FOR THE TREATMENT OF KIDNEY DISEASE

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
JPS4864088A (es) 1971-12-13 1973-09-05
JPS5414986B2 (es) 1973-10-02 1979-06-11
DK1037886T3 (da) 1997-12-12 2003-08-25 Abbott Lab Triazin angiogeneseinhibitorer
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
BRPI0506919A (pt) 2004-01-20 2007-06-05 Merck & Co Inc composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal deste farmaceuticamente aceitável
JP4864088B2 (ja) 2005-08-11 2012-01-25 エス アール ユー バイオシステムズ，インコーポレイテッド 標識不使用下での結合検出と蛍光増幅を組合せた格子に基づくセンサー及びセンサー用読取システム
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896158B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
WO2008069222A1 (en) 2006-12-05 2008-06-12 Semiconductor Energy Laboratory Co., Ltd. Plasma display panel and field emission display
DE102007054416A1 (de) 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
RS54736B1 (sr) 2008-05-23 2016-10-31 Poxel Sas Postupak za sintezu derivata 3,6-dihidro-1,3,5-triazina
CA2732157C (en) 2008-07-29 2016-04-12 Poxel Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
BRPI0922650A2 (pt) 2008-12-12 2017-07-11 Poxel Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
SI2355829T1 (sl) 2008-12-12 2015-03-31 Poxel S.A.S. Kombinacija inzulina z derivati triazina in njegova uporaba za zdravljenje diabetesa
KR101921934B1 (ko) 2009-02-13 2018-11-26 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
ES2577930T3 (es) 2010-06-09 2016-07-19 Poxel Derivados de triazina para retrasar el inicio de la diabetes tipo 1
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
WO2012072663A1 (en) 2010-12-01 2012-06-07 Poxel Separation of triazine derivatives enantiomers using tartaric acid
US9211263B2 (en) * 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
JP6175074B2 (ja) * 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
WO2014160524A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Cardio- metabolic and cascular effects of glp-1 metabolites
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
EP3217987A4 (en) 2014-11-10 2018-06-20 Merck Sharp & Dohme Corp. Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
CN105990398B (zh) 2015-02-16 2019-01-11 上海和辉光电有限公司 有机发光二极管显示器及其制造方法
MX2018011088A (es) 2016-03-16 2018-11-22 Boehringer Ingelheim Int Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2020003243A (es) 2017-10-02 2020-09-18 Poxel Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
WO2019236844A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease

Also Published As

Publication number Publication date
IL279174A (en) 2021-01-31
ES2929994T3 (es) 2022-12-05
KR20200130281A (ko) 2020-11-18
PH12020551159A1 (en) 2021-06-07
EP3801542A1 (en) 2021-04-14
BR112020024643A2 (pt) 2021-03-02
CA3102412A1 (en) 2019-12-12
TW202015696A (zh) 2020-05-01
US20200215072A1 (en) 2020-07-09
TWI846700B (zh) 2024-07-01
AU2019282727A1 (en) 2020-11-26
US12036226B2 (en) 2024-07-16
SG11202007172YA (en) 2020-08-28
EP3801542B1 (en) 2022-08-10
WO2019236844A1 (en) 2019-12-12
US11266652B2 (en) 2022-03-08
JP2021529728A (ja) 2021-11-04
CN111918655B (zh) 2024-05-31
US20220387437A1 (en) 2022-12-08
CN111918655A (zh) 2020-11-10

Similar Documents

Publication Publication Date Title
PH12020551159A1 (en) Methods of treating subjects having diabetes with chronic kidney disease
PH12015502275A1 (en) Therapuetic uses of empagliflozin
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
EP3773880C0 (en) THERAPEUTIC MODULATION TO TREAT BLOOD GLUCOSE ABNORMALITY, INCLUDING TYPE 2 DIABETES, AND/OR TO REDUCE HBA1C LEVELS
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2021011711A (es) Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica.
MX2021000976A (es) Compuestos para usarse en el tratamiento de trastornos renales.
MX2019014988A (es) Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.
AR117669A1 (es) Métodos para tratar sujetos que padecen diabetes con enfermedad renal crónica
MX2021009702A (es) Metodos para tratar el dolor de la superficie ocular.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201890007A1 (ru) Мультипептидная композиция
MX2022002947A (es) Avocatina b para el tratamiento de enfermedades y afecciones.
WO2015175008A8 (en) Methods of treating chronic kidney disease characterized by macroalbuminuria
WO2019236747A3 (en) Cyclic peptide compounds and methods of use thereof
EA202090988A1 (ru) Способы лечения синдрома фелан-макдермид с помощью дибензодиазепинонов фарнезила